Tag:
ASA404
Latest Headlines
Latest Headlines
Novartis ($NVS) writes off $120M and the once-promising ASA404
Seven months after investigators pulled the plug on a failed late-stage trial of the once-promising cancer therapy ASA404, Novartis ( $NVS ) announced it is dumping its partnership with Antisoma and
Antisoma shares crater as lead cancer drug flunks PhIII
Shares of the U.K.'s Antisoma suffered a meltdown Monday morning as investors reacted to the news that its lead program suffered a catastrophic Phase III failure. The developer decided to halt the
Antisoma, Novartis launch ASA404 trial in Japan
Researchers for Antisoma and Novartis have begun enrolling patients in Japan for a late-stage trial of ASA404 as a first-line treatment for non-small cell lung cancer--a big step toward seeking an
Antisoma shares spike on positive cancer data
Antisoma saw its shares spike on positive data from a trial in non-small cell lung cancer. "These positive results strongly support our earlier trial findings, which showed that adding ASA404
